Skip Navigation

European Heart Journal 1996 17(11):1703-1709;
Copyright © 1996 by the European Society of Cardiology.
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Choudhury, L.
Right arrow Articles by Camici, P. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Choudhury, L.
Right arrow Articles by Camici, P. G.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 1996 The European Society of Cardiology

Myocardial beta adrenoceptor density in primary and secondary left ventricular hypertrophy

L. Choudhury, S. D. Rosen, D. C. Lefroy, P. Nihoyannopoulos, C. M. Oakley and P. G. Camici

Cyclotron Unit, MRC Clinical Sciences Centre, and Royal Postgraduate Medical School, Hammersmith Hospital London, U.K

Received 6 February 1996; accepted 13 February 1996.

Correspondence: Paolo G. Camici, MD, Cylotron Unit, MRC Clinical Sciences Centre, Hammersmith Hospital, Du Cane Road, London W12 0HS, U.K.

Abstract

OBJECTIVES: Myocardial ß-adrenoceptor density has been found to be reduced in hypertrophic cardiomyopathy, even when systolic function is preserved. Our purpose in the current study was to investigate whether ß-adrenoceptor down-regulation was unique to hypertrophic cardiomyopathy, or is also present in secondary myocardial hypertrophy.

METHODS: Myocardial ß-adrenoceptor density was measured in 11 patients with hypertrophic cardiomyopathy, eight patients with left ventricular hypertrophy secondary to arterial hypertension or aortic valve disease and 18 normal control subjects, using positron emission tomography with 11C-CGP-12177 as the myocardial ß-adrenoceptor ligand.

RESULTS: Reflecting the natural incidence of the conditions, the age of the hypertrophic cardiomyopathy patients was 37 (10) [mean (SD), range 20–51] years and that of the secondary hypertrophy patients 64 (18), [range 26–80] years; P<0.01. The controls' ages were 50 (13), [range 21–65] years; however, since ß-adrenoceptor density is known to be influenced by age, the controls' data was split into groups matched to the hypertrophic cardiomyopathy and secondary hypertrophy patient sets. For the hypertrophic cardiomyopathy patients, mean left ventricular ß-adrenoceptor was 7.70 (186) pmol . g–1 compared to 10.17 (244) pmol . g–1 for a matched set of 15 controls; P<0.01. In secondary left ventricular hypertrophy, ß-adrenoceptor was 6.35 (1.70) pmol . g–1 compared to 9.16 (2.00)pmol . g–1 for a matched set of 10 controls; P<0.01. Plasma noradrenaline was 5.5 (2.2)nmol . 1–1 in hypertrophic cardiomyopathy and 2.5 (1.0)nmol. 1–1 for the matched controls; P<0.01. The results for adrenaline were 2.2 (1.1) vs 0.4 (0.3) nmol . 1–1 respectively; P<0.001. For the secondary hypertrophy patients, the corresponding figures were 2.5 (1.2) vs 2.5 (1.0) nmol . 1–1 for noradrenaline for patients and controls respectively (P=ns); and for adrenaline 0.2 (0.1) and 0.3 (0.2) nmol . 1–1 respectively, P=ns. On multiple regression analysis, no relationships could be demonstrated amongst plasma catecholamines, ß-adrenoceptor, myocardial blood flow and echocardiographic E/A ratio and fractional shortening.

CONCLUSION: Myocardial ß-adrenoceptor density appears to be comparably decreased in both primary and secondary left ventricular hypertrophy in the presence of preserved left ventricular systolic function.

Key Words: Beta adrenoceptors • hypertrophic cardiomyopathy • left ventricular hypertrophy • sympathetic nervous system • positron emission tomography • arterial hypertension, catecholamines


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 JNMHome page
M. Momose, S. Reder, D. M. Raffel, P. Watzlowik, H.-J. Wester, N. Nguyen, P. H. Elsinga, F. M. Bengel, J. Remien, and M. Schwaiger
Evaluation of Cardiac {beta}-Adrenoreceptors in the Isolated Perfused Rat Heart Using (S)-11C-CGP12388
J. Nucl. Med., March 1, 2004; 45(3): 471 - 477.
[Abstract] [Full Text]

Home page
 Circ. Res.Home page
M. Iwata, T. Yoshikawa, A. Baba, T. Anzai, I. Nakamura, Y. Wainai, T. Takahashi, and S. Ogawa
Autoimmunity Against the Second Extracellular Loop of {beta}1-Adrenergic Receptors Induces {beta}-Adrenergic Receptor Desensitization and Myocardial Hypertrophy In Vivo
Circ. Res., March 30, 2001; 88(6): 578 - 586.
[Abstract] [Full Text] [PDF]

Home page
 HeartHome page
P. G Camici
IMAGING TECHNIQUES: Positron emission tomography and myocardial imaging
Heart, April 1, 2000; 83(4): 475 - 480.
[Full Text]

Home page
 J. Appl. Physiol.Home page
O. E. Suman, D. Hasten, M. J. Turner, M. R. Rinder, R. J. Spina, and A. A. Ehsani
Enhanced inotropic response to dobutamine in strength-trained subjects with left ventricular hypertrophy
J Appl Physiol, February 1, 2000; 88(2): 534 - 539.
[Abstract] [Full Text] [PDF]

Home page
 Pharmacol. Rev.Home page
N. Dzimiri
Regulation of beta -Adrenoceptor Signaling in Cardiac Function and Disease
Pharmacol. Rev., September 1, 1999; 51(3): 465 - 502.
[Abstract] [Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.